Company Profile

NovaVax Inc
Profile last edited on: 6/9/2024      CAGE: 1UCZ4      UEI: ZXHWXURNS6W8

Business Identifier: Clinical-stage biotechnology company focused on discovery and development of innovative vaccines
Year Founded
1987
First Award
2009
Latest Award
2009
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

700 Quince Orchard Road
Gaithersburg, MD 20878
   (240) 268-2000
   info@novavax.com
   www.novavax.com
Location: Single
Congr. District: 06
County: Montgomery

Public Profile

Founded in 1987 but not SBIR involved for several years and then on a limited basis, Novavax, Inc. is headquartered in Gaithersburg, MD functioning as a clinical-stage biopharmaceutical company that came into existence after IGI Labs, Inc (AMEX:IGI) divested itself of its biotech division to its stockholders ...immediately making the new firm a publicly traded entity. Novavax, Inc., together with its subsidiary, Novavax AB - a late-stage biotechnology company - organizes around discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates had included ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. The firm's lead adjuvant has been Matrix-M - used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company also developed RSV F vaccine for older adults (60 years and older) that went through Phase II clinical trial, as well as for healthy children between six months to five years of age. In addition, the firm develops nanoparticle vaccine candidates for clinic testing against ebola virus also taken through Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company developed COVID-19 vaccine for the coronavirus that had cause pneumonia-like symptoms. The firm also had a co-marketing agreement with GE Healthcare for a pandemic influenza vaccine solution,

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : NVAX
IP Holdings
75-99

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2009 1 NIH $246,812
Project Title: Development of a Virus-Like Particle (VLP) Vaccine for RSV

Key People / Management

  Stanley C Erck -- President

  Rahul Singhvi -- former CEO, President, Director and Member of Gov. Relations Committee

  Frederick W Driscoll -- Vice President & Chief Financial Officer & Treasurer

  Gregory M Glenn -- Senior Vice President of R&D

  Timothy Jon Hahn -- Sr. VP of Global Manufacturing Operations

  Penny M Heaton -- Director

  Jill Hoyt -- EVP of Human Resources

  Barclay A Phillips -- Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer

  John Joseph Trizzino -- VP, Chief Business Officer & CFO